e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Modern radiotherapy as a curative treatment modality for stage III NSCLC
E. Troost (Dresden, Germany)
Source:
International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Session:
Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Session type:
Symposium
Number:
5126
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Troost (Dresden, Germany). Modern radiotherapy as a curative treatment modality for stage III NSCLC. International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Indcution chemotherapy and radiotherapy
vs.
induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006
Postoperative adjuvant treatment in stage III NSCLC
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC?
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009
Chemoradiotherapy with or without surgical resection for stage III NSCLC
Source: Breathe 2010; 6: 275
Year: 2010
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 399s
Year: 2002
Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC
Source: ISSN=ISSN 1810-6838, ISBN=, page=380
Year: 2007
Combined modality treatment for NSCLC
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Prerequisites, potential and limits of thoracic surgery with curative intent for stage III NSCLC
Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Year: 2019
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97
Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Year: 2004
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
Source: Eur Respir Rev 2015; 24: 340-355
Year: 2015
Adjuvant chemotherapy and prophylactic cranial irradiation in the combined treatment for the operable patients with small cell lung cancer I-III stage
Source: Eur Respir J 2005; 26: Suppl. 49, 75s
Year: 2005
Role of adjuvant/neoadjuvant treatment in stage I NSCLC
Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC)
Year: 2014
Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy)
Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course
Year: 2011
Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept